A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Patel, Nima ^a   Vogel, Robert ^b   Chandra Kuntal, Kumar ^a   Glasgow, Wayne ^a   Kelavkar, Uddhav ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; PROSTATE SPECIFIC ANTIGEN; SPHINGOMYELIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHOSPHOLIPID BLOOD LEVEL; PREDICTION; PROGNOSIS; PROSTATE CANCER; SCREENING TEST; VERY ELDERLY; BLOOD; CANCER GRADING; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPIDS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOMYELINS;

EID: 84897401502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088841     Document Type: Article

References (46)

1. Henrik G (2003) Prostate cancer epidemiology. The Lancet 361: 859-864.
2. Clarke RA, Schirra HJ, Catto JW, Lavin MF, Gardiner RA (2010) Markers for Detection of Prostate Cancer. Cancers 2: 1125-1154.
3. Huang M, Narita S, Numakura K, Tsuruta H, Saito M, et al. (2012) A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. The Prostate 72: 1779-1788.
4. Chan JM, Jou RM, Carroll PR (2004) The relative impact and future burden of prostate cancer in the United States. J Urol 172: S13-16; discussion S17.
5. (2000) Knowledge, attitudes, and screening practices among older men regarding prostate cancer. American Journal of Public Health 90: 1595-1600.
6. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI (2003) Pathological and molecular aspects of prostate cancer. The Lancet 361: 955-964. (Pubitemid 36332115)
7. Jump DB (2004) Fatty Acid Regulation of Gene Transcription. Critical Reviews in Clinical Laboratory Sciences 41: 41-78.
8. Brasky TM, Till C, White E, Neuhouser ML, Song X, et al. Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. American Journal of Epidemiology 173: 1429-1439.
9. Zhou X, Lawrence TJ, He Z, Pound CR, Mao J, et al. The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Experimental and Molecular Pathology 92: 105-110.
10. Cvetković B, Vučić V, Cvetković Z, Popović T, Glibetić M (2012) Systemic alterations in concentrations and distribution of plasma phospholipids in prostate cancer patients. Medical Oncology 29: 809-814.
11. Tewari R, Rajender S, Natu SM, Dalela D, Goel A, et al. (2012) Diet, Obesity, and Prostate Health: Are We Missing the Link? J Androl 33: 763-776.
12. (2007) WCRF/AICR's Second Expert Report, Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective - See more at: http://www.dietandcancerreport.org/expert-report/index. php #sthash.ibJBGije. dpuf. http://www.dietandcancerreport.org/.
13. Yang YJ, Lee SH, Hong SJ, Chung BC (1999) Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry 32: 405-409. (Pubitemid 29536171)
14. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917.
15. Devaiah SP, Roth MR, Baughman E, Li M, Tamura P, et al. (2006) Quantitative profiling of polar glycerolipid species from organs of wild-type Arabidopsis and a PHOSPHOLIPASE Da1 knockout mutant. Phytochemistry 67: 1907-1924. (Pubitemid 44291405)
16. Bartz R, Li W-H, Venables B, Zehmer JK, Roth MR, et al. (2007) Lipidomics reveals that adiposomes store ether lipids and mediate phospholipid traffic. Journal of Lipid Research 48: 837-847. (Pubitemid 46557888)
17. Welti R, Li M, Li W, Sang Y, Biesiada H, et al. (2002) Profiling membrane lipids in plant stress response. J Biol Chem 277: 31994-32002.
18. Brügger B, Erben G, Sandhoff R, Wieland FT, Lehmann WD (1997) Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proceedings of the National Academy of Sciences 94: 2339-2344. (Pubitemid 27136876)
19. Liebisch G, Lieser B, Rathenberg J, Drobnik W, Schmitz G (2004) High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1686: 108-117. (Pubitemid 39446883)
20. Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375. (Pubitemid 36284936)
21. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, et al. (2003) Early Biomarkers of Stroke. Clinical Chemistry 49: 1733-1739. (Pubitemid 37194242)
22. Sartor MA, Leikauf GD, Medvedovic M (2009) LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data. Bioinformatics 25: 211-217.
23. Kim S-Y, Volsky D (2005) PAGE: Parametric Analysis of Gene Set Enrichment. BMC Bioinformatics 6: 144.
24. Bretz F, Landgrebe J, Brunner E (2005) Design and Analysis of Two-color Microarray Experiments Using Linear Models. Methods of Information in Medicine 44: 423-430. (Pubitemid 41044341)
25. Bretz F, Landgrebe J, Brunner E (2005) Multiplicity Issues in Microarray Experiments. Methods of Information in Medicine 44: 431-437. (Pubitemid 41044342)
26. Benjamini Y, Yekutieli D (2005) False Discovery Rate-Adjusted Multiple Confidence Intervals for Selected Parameters. Journal of the American Statistical Association 100: 71-81.
27. Krzanowski WJ, Hand DJ (2009) ROC Curves for Continuous Data. CRC Press, Baco Raton.
28. Pepe MS (2004) The Statistical Evaluation of Medical Tests for Classification and Prediction. .
29. Tsai C-A, Hsueh H-m, Chen JJ (2003) Estimation of False Discovery Rates in Multiple Testing: Application to Gene Microarray Data. Biometrics 59: 1071-1081. (Pubitemid 38021237)
30. Huynh-Thu VA, Saeys Y, Wehenkel L, Geurts P (2012) Statistical interpretation of machine learning-based feature importance scores for biomarker discovery. Bioinformatics 28: 1766-1774.
31. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry 39: 561-577. (Pubitemid 23118304)
32. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, et al. (2009) Prostate Specific Antigen Best Practice Statement: 2009 Update. The Journal of Urology 182: 2232-2241.
33. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, et al. (2009) Mortality Results from a Randomized Prostate-Cancer Screening Trial. New England Journal of Medicine 360: 1310-1319.
34. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level # 4.0 ng perMilliliter. New England Journal of Medicine 350: 2239-2246.
35. Heidenreich A BM, Joniau S, Mason MD, Matveev V (2010) Guidelines on prostate cancer. European Association of Urology.
36. Awwad HM, Geisel J, Obeid R (2012) The role of choline in prostate cancer. Clinical Biochemistry.
37. Brett AS, Ablin RJ (2011) Prostate-Cancer Screening - What the U.S. Preventive Services Task Force Left Out. New England Journal of Medicine 365: 1949-1951.
38. Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, et al. (2007) DNA methylation paradigm shift: 15-Lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation. Prostaglandins & Other Lipid Mediators 82: 185-197. (Pubitemid 44880172)
39. Punnonen K, Hietanen E, Auvinen O, Punnonen R (1989) Phospholipids and fatty acids in breast cancer tissue. Journal of Cancer Research and Clinical Oncology 115: 575-578. (Pubitemid 20059005)
40. Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, et al. (2012) Dietary Fatty Acid Intake and Prostate Cancer Survival in Örebro County, Sweden. American Journal of Epidemiology 176: 240-252.
41. Min H, Lim S, Chung B, Moon M (2011) Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer. Analytical and Bioanalytical Chemistry 399: 823-830.
42. Norrish AE, Skeaff CM, Arribas GLB, Sharpe SJ, Jackson RT (1999) Prostate cancer risk and consumption of fish oils: A dietary biomarker-based case-control study. Br J Cancer 81: 1238-1242.
43. Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, et al. (2008) Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. The American Journal of Clinical Nutrition 88: 1353-1363.
44. Arab L (2003) Biomarkers of Fat and Fatty Acid Intake. The Journal of Nutrition 133: 925S-932S.
45. Leaf D, Connor W, Barstad L, Sexton G (1995) Incorporation of dietary n-3 fatty acids into the fatty acids of human adipose tissue and plasma lipid classes. The American Journal of Clinical Nutrition 62: 68-73.
46. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, et al. (2001) Phases of Biomarker Development for Early Detection of Cancer. J Natl Cancer Inst 93:1054-1061. (Pubitemid 32717537)